Johnson & Johnson Investor Presentation — April 2022

Document content

April 19, 2022 Cautionary Note on Forward -looking Statements

This presentation contains “forward -looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regar ding, among other things: future operating and financial

performance, product development, market position and business strategy, and the anticipated separation of the Company’s Cons umer Health business. The reader is cautioned not to rely on

these forward -looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties

materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncer tainties include, but are not limited to: economic factors, such as

interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patent s attained by competitors; challenges inherent in new product

research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commer cial success for new and existing products; challenges to patents; the

impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business comb inations and divestitures; manufacturing difficulties or delays, internally

or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significan t adverse litigation or government action, including related to product liability

claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health c arecost containment; changes in behavior and spending patterns of